Shopping Cart
- Remove All
- Your shopping cart is currently empty
McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor used for researching metabolic diseases.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $350 | In Stock | |
5 mg | $970 | In Stock | |
10 mg | $1,200 | In Stock | |
25 mg | $1,590 | In Stock | |
50 mg | $1,980 | In Stock | |
100 mg | $2,500 | In Stock | |
500 mg | $5,000 | In Stock |
Description | McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor used for researching metabolic diseases. |
In vivo | Significantly reducing the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, McN3716 (Methyl palmoxirate, MEP) achieves inhibition of brain mitochondrial β-oxidation. Notably, 15-HETE remains unaffected. McN3716 treatment leads to a significant 34% reduction in the level of 6-keto-PGF1α, a byproduct of PGI2 (prostacyclin). Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to the vehicle[1]. |
Alias | NSC359682, Methyl palmoxirate |
Molecular Weight | 298.46 |
Formula | C18H34O3 |
Cas No. | 69207-52-9 |
Smiles | CCCCCCCCCCCCCCC1(CO1)C(=O)OC |
Relative Density. | 0.944g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 2.98 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.